2022 World Conference on Lung Cancer (ePosters)-EP08.02-026. Real-world Efficacy of EGFR-TKI in Advanced NSCLC and Clinical Predictors of Outcome in Maharaj Nakorn Chiangmai Hospital in Thailand.

EP08.02-026. Real-world Efficacy of EGFR-TKI in Advanced NSCLC and Clinical Predictors of Outcome in Maharaj Nakorn Chiangmai Hospital in Thailand.

Back to course

Pdf Summary

This study examines the real-world efficacy of EGFR TKIs in treating advanced non-small-cell lung cancer (NSCLC) in Thailand. The study focuses on the reimbursement policy for EGFR TKIs, which limited access to these targeted agents for only a subset of NSCLC patients in Thailand, primarily civil servants. The study collected data from 205 patients with advanced NSCLC who received EGFR TKIs at a single university-based teaching hospital in Thailand. The available EGFR TKIs included Gefitinib, Erlotinib, Afatinib, and Osimertinib. The study aimed to analyze treatment outcomes, toxicity, and clinical factors associated with outcome in EGFR-TKI treated patients.<br /><br />The study found that the available EGFR TKIs demonstrated consistent efficacy in terms of overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) across various lines of treatment. There were no statistically significant differences in ORR, PFS, or OS among the different EGFR TKIs or among different EGFR mutation status. Osimertinib, used in patients with acquired T790M mutation, also showed similar outcomes to prior studies.<br /><br />The study did not identify any specific factors in patients' baseline characteristics that were associated with PFS or OS. The most common adverse events related to EGFR TKIs were mild dermatologic toxicities, such as rash, dry skin, and acneiform rash.<br /><br />In conclusion, this study provides real-world evidence for the efficacy and tolerability of EGFR TKIs in treating advanced NSCLC in a resource-constrained setting. The findings support the use of EGFR TKIs as the preferred treatment of choice whenever possible in advanced EGFR-mutant NSCLC patients. Further research is needed to validate these findings and explore potential predictors of treatment outcomes in this patient population.

Asset Subtitle

Chaiyut Charoentum

Meta Tag

Speaker Chaiyut Charoentum

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

EGFR TKIs

non-small-cell lung cancer

Thailand

reimbursement policy

access to targeted agents

Gefitinib

Erlotinib

Afatinib

Osimertinib

treatment outcomes